1. Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
- Author
-
Biegus, Jan, Demissei, Biniyam, Postmus, Douwe, Cotter, Gad, Davison, Beth A, Felker, G Michael, Filippatos, Gerasimos, Gimpelewicz, Claudio, Greenberg, Barry, Metra, Marco, Severin, Thomas, Teerlink, John R, Voors, Adriaan A, and Ponikowski, Piotr
- Subjects
Cardiovascular ,Acute Disease ,Aged ,Aged ,80 and over ,Bilirubin ,Creatinine ,Female ,Heart Failure ,Humans ,Kidney Diseases ,Liver Diseases ,Male ,Middle Aged ,Prognosis ,Severity of Illness Index ,Acute heart failure ,Liver dysfunction ,Kidney dysfunction ,MELD-XI score ,Cardiorespiratory Medicine and Haematology - Abstract
AimsEpisodes of acute heart failure (AHF) may lead to end-organ dysfunction. In this post hoc analysis of the Relaxin in Acute Heart Failure trial, we used the MELD-XI (Model of End-Stage Liver Dysfunction) score to examine hepatorenal dysfunction in patients with AHF.Methods and resultsOn admission, the MELD-XI score was elevated (abnormal) in 918 (82%) patients, with 638 (57%) having isolated renal dysfunction (creatinine > 1 mg/dL), 73 (6.5%) isolated liver dysfunction (bilirubin > 1 mg/dL), and 207 (18.5%) coexisting dysfunction of the kidneys and the liver (both creatinine and bilirubin > 1 mg/dL). The percentage of patients with elevated MELD-XI score remained constant through a 60 day follow-up, as we observed a gradual decrease of liver dysfunction prevalence, counterbalanced by an increase in renal dysfunction. Serelaxin treatment was associated with a lower MELD-XI score on Day 2 and Day 5 (both P
- Published
- 2019